|
Q |
Aia1 |
Adjuvant induced arthritis QTL 1 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
NCBI chr20:2,646,395...4,597,031
|
|
Q |
Aia2 |
Adjuvant induced arthritis QTL 2 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
NCBI chr 4:39,505,275...73,892,441
|
|
Q |
Aia3 |
Adjuvant induced arthritis QTL 3 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
NCBI chr 4:86,730,991...131,730,991
|
|
Q |
Aia4 |
Adjuvant induced arthritis QTL 4 |
|
IEA |
|
RGD |
PMID:9780220 |
RGD:61035 |
NCBI chr15:55,596,089...91,365,858
|
|
Q |
Bw1 |
Body weight QTL1 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 2:43,171,017...83,575,226
|
|
Q |
Bw19 |
Body weight QTL 19 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr 7:1...44,782,185
|
|
Q |
Bw2 |
Body weight QTL2 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 4:9,940,885...44,463,908
|
|
Q |
Bw3 |
Body weight QTL3 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 8:69,349,194...112,783,834
|
|
Q |
Bw4 |
Body weight QTL4 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr 9:5,109,826...50,109,826
|
|
Q |
Bw5 |
Body weight QTL5 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr14:11,030,812...30,320,092
|
|
Q |
Bw60 |
Body weight QTL60 |
|
IEA |
|
RGD |
PMID:11087657 |
RGD:619690 |
NCBI chr14:79,950,921...95,876,975
|
|
Q |
Bw61 |
Body weight QTL61 |
|
IEA |
|
RGD |
PMID:11853145 |
RGD:619672 |
NCBI chr 1:173,108,781...218,108,781
|
|
Q |
Cari1 |
Carrageenan-induced inflammation QTL 1 |
|
IEA |
|
RGD |
PMID:10087293 |
RGD:69693 |
NCBI chr10:53,797,385...107,211,142
|
|
Q |
Cari2 |
Carrageenan-induced inflammation QTL 2 |
|
IEA |
|
RGD |
PMID:10087293 |
RGD:69693 |
NCBI chr 2:141,596,551...202,447,032
|
|
Q |
Ciaa2 |
CIA Autoantibody QTL 2 |
|
IEA |
|
RGD |
PMID:10857786 |
RGD:61066 |
NCBI chr10:63,221,094...107,211,142
|
|
Q |
Eau1 |
Experimental allergic uveoretinitis QTL 1 |
|
IEA |
|
RGD |
PMID:10323205 |
RGD:61073 |
NCBI chr 4:70,362,013...132,642,728
|
|
Q |
Eau2 |
Experimental allergic uveoretinitis QTL 2 |
|
IEA |
|
RGD |
PMID:10323205 |
RGD:61073 |
NCBI chr12:8,525,423...28,064,601
|
|
Q |
Eau3 |
Experimental allergic uveoretinitis QTL 3 |
|
IEA |
|
RGD |
PMID:10323205 |
RGD:61073 |
NCBI chr10:34,490,559...45,579,777
|
|
Q |
Hcar13 |
Hepatocarcinoma resistance QTL 13 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr 4:1...32,584,199
|
|
Q |
Hcar14 |
Hepatocarcinoma resistance QTL 14 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr18:51,464,733...83,218,561
|
|
Q |
Hcar4 |
Hepatocarcinoma resistance QTL 4 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 1:193,422,268...214,537,671
|
|
Q |
Hcar5 |
Hepatocarcinoma resistance QTL 5 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 1:214,537,555...226,660,468
|
|
Q |
Hcar6 |
Hepatocarcinoma resistance QTL 6 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
|
|
Q |
Hcar7 |
Hepatocarcinoma resistance QTL 7 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 4:70,808,386...115,808,386
|
|
Q |
Hcar8 |
Hepatocarcinoma resistance QTL 8 |
|
IEA |
|
RGD |
PMID:10850431 |
RGD:619609 |
NCBI chr 4:123,143,783...168,143,783
|
|
Q |
Hcas5 |
Hepatocarcinoma susceptibility QTL 5 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr 1:176,426,412...257,976,495
|
|
Q |
Hcas6 |
Hepatocarcinoma susceptibility QTL 6 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr14:39,057,237...83,368,335
|
|
Q |
Hcas7 |
Hepatocarcinoma susceptibility QTL 7 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr15:2,266,368...46,921,453
|
|
Q |
Iddm3 |
Insulin dependent diabetes mellitus QTL 3 |
|
IEA |
|
RGD |
PMID:10441739 |
RGD:61481 |
NCBI chr 2:189,599,258...234,599,258
|
|
Q |
Insul2 |
Insulin level QTL 2 |
|
IEA |
|
RGD |
PMID:9819774 |
RGD:69703 |
NCBI chr20:6,691,706...17,489,458
|
|
Q |
Lnnr1 |
Liver neoplastic nodule remodeling QTL 1 |
|
IEA |
|
RGD |
PMID:12672032 |
RGD:629574 |
NCBI chr 7:34,293,282...79,293,282
|
|
Q |
Lnnr2 |
Liver neoplastic nodule remodeling QTL 2 |
|
IEA |
|
RGD |
PMID:12672032 |
RGD:629574 |
NCBI chr 1:233,948,574...260,522,016
|
|
Q |
Lnnr3 |
Liver neoplastic nodule remodeling QTL 3 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr 2:1...41,244,106
|
|
Q |
Lnnr4 |
Liver neoplastic nodule remodeling QTL 4 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr13:1...42,356,786
|
|
Q |
Lnnr5 |
Liver neoplastic nodule remodeling QTL 5 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr13:59,874,408...85,581,182
|
|
Q |
Lnnr6 |
Liver neoplastic nodule remodeling QTL 6 |
|
IEA |
|
RGD |
PMID:15185337 |
RGD:737884 |
NCBI chr13:74,862,117...85,581,182
|
|
Q |
Niddm1 |
Non-insulin dependent diabetes mellitus QTL 1 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr 1:218,753,689...245,907,899
|
|
Q |
Niddm14 |
Non-insulin dependent diabetes mellitus QTL 14 |
|
IEA |
|
RGD |
PMID:9585427 |
RGD:61072 |
NCBI chr 7:84,257,275...129,257,275
|
|
Q |
Niddm15 |
Non-insulin dependent diabetes mellitus QTL 15 |
|
IEA |
|
RGD |
PMID:9585427 |
RGD:61072 |
NCBI chr14:1,217,606...11,030,812
|
|
Q |
Niddm2 |
Non-insulin dependent diabetes mellitus QTL 2 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr 2:144,599,348...189,599,348
|
|
Q |
Niddm3 |
Non-insulin dependent diabetes mellitus QTL 3 |
|
IEA |
|
RGD |
PMID:8528247 |
RGD:61082 |
NCBI chr10:61,345,413...82,564,856
|
|
Q |
Niddm37 |
Non-insulin dependent diabetes mellitus QTL 37 |
|
IEA |
|
RGD |
PMID:10218444 |
RGD:619676 |
NCBI chr14:11,030,622...95,876,975
|
|
Q |
Niddm38 |
Non-insulin dependent diabetes mellitus QTL 38 |
|
IEA |
|
RGD |
PMID:10218444 |
RGD:619676 |
NCBI chr19:10,323,180...23,069,265
|
|
Q |
Niddm39 |
Non-insulin dependent diabetes mellitus QTL 39 |
|
IEA |
|
RGD |
PMID:10218444 |
RGD:619676 |
NCBI chr 3:94,856,903...159,898,684
|
|
Q |
Niddm40 |
Non-insulin dependent diabetes mellitus QTL 40 |
|
IEA |
|
RGD |
PMID:10902185 |
RGD:619671 |
NCBI chr 1:136,745,990...163,747,690
|
|
Q |
Niddm41 |
Non-insulin dependent diabetes mellitus QTL 41 |
|
IEA |
|
RGD |
PMID:10902185 |
RGD:619671 |
NCBI chr17:1...37,830,672
|
|
Q |
Scl29 |
Serum cholesterol level QTL 29 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 6:35,098,709...71,636,405
|
|
Q |
Scwia1 |
Streptococcal cell wall induced arthritis QTL 1 |
|
IEA |
|
RGD |
PMID:10331011 |
RGD:61064 |
NCBI chr 4:106,805,662...151,805,662
|
|
Q |
Slep1 |
Serum leptin concentration QTL 1 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 2:43,171,017...184,114,403
|
|
Q |
Slep2 |
Serum leptin concentration QTL 2 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 6:16,536,140...71,636,405
|
|
Q |
Stl10 |
Serum triglyceride level QTL 10 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 4:21,333,343...44,463,908
|
|
Q |
Stl11 |
Serum triglyceride level QTL 11 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr 7:119,513,385...135,012,528
|
|
Q |
Stl12 |
Serum triglyceride level QTL 12 |
|
IEA |
|
RGD |
PMID:14724732 |
RGD:737686 |
NCBI chr11:66,422,148...86,241,447
|
|
Q |
Tls1 |
T-lymphoma susceptibility QTL 1 |
|
IEA |
|
RGD |
PMID:10360666 |
RGD:619600 |
NCBI chr 5:90,450,144...135,450,144
|
|
Q |
Tls2 |
T-lymphoma susceptibility QTL 2 |
|
IEA |
|
RGD |
PMID:10360666 |
RGD:619600 |
NCBI chr 7:80,221,299...109,401,111
|
|
Q |
Tls3 |
T-lymphoma susceptibility QTL 3 |
|
IEA |
|
RGD |
PMID:10360666 |
RGD:619600 |
NCBI chr10:51,774,612...95,600,334
|
|